Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Ensysce Biosciences Inc ENSC

Alternate Symbol(s):  ENSCW

Ensysce Biosciences, Inc. is a clinical-stage pharmaceutical company. The Company develops solutions for severe pain relief while reducing the potential for opioid misuse, abuse, and overdose. Its pipeline includes two new drug platforms: an abuse-resistant opioid prodrug technology, the Trypsin Activated Abuse Protection (TAAP) platform, and an over-dose protection opioid prodrug technology... see more

Recent & Breaking News (NDAQ:ENSC)

Ensysce Biosciences Releases Updated Investor Presentation Available Via Investor Relations Website

ACCESS Newswire June 7, 2023

Ensysce Biosciences to Participate in Upcoming Industry Events

ACCESS Newswire June 6, 2023

Ensysce Biosciences Reports First Quarter 2023 Financial Results

ACCESS Newswire May 15, 2023

Ensysce Biosciences, Inc. Announces Closing of $7 Million Public Offering

ACCESS Newswire May 12, 2023

Ensysce Biosciences, Inc. Announces Pricing of $7 Million Public Offering

ACCESS Newswire May 10, 2023

Ensysce Biosciences Announces Successful Completion of Ground-Breaking Study on Overdose Protection

ACCESS Newswire May 9, 2023

Ensysce CEO Dr. Lynn Kirkpatrick To Present Featured Case Study of MPAR Overdose Protection Platform Accelerated Development

ACCESS Newswire April 19, 2023

Ensysce Biosciences Announces Updated Investor Presentation Available Via Investor Relations Website

ACCESS Newswire April 11, 2023

Ensysce Biosciences Announces Positive Results from Oral Human Abuse Potential Trial for PF614

ACCESS Newswire April 3, 2023

Ensysce Biosciences Reports Fourth Quarter and Full Year 2022 Financial Results

ACCESS Newswire March 30, 2023

Ensysce Biosciences Announces Completion of Enrollment for Groundbreaking Opioid Overdose Protection Study

ACCESS Newswire March 22, 2023

Dr. Lynn Kirkpatrick, Featured Speaker to Discuss Ensysce Overdose Protection Platform at DCAT Seminar

ACCESS Newswire March 6, 2023

Ensysce Biosciences Announces Critical Step in Human Abuse Potential Study of PF614 With Database Lock

ACCESS Newswire February 28, 2023

Ensysce Biosciences Provides Corporate Update

ACCESS Newswire February 23, 2023

Ensysce Biosciences Receives Positive Nasdaq Listing Determination

ACCESS Newswire February 15, 2023

Ensysce Biosciences to Present its Overdose Protection Program at the 4th Annual NIH 'HELPING END ADDICTION LONG-TERM' (HEAL) Meeting

ACCESS Newswire February 14, 2023

Ensysce Biosciences, Inc. Announces Closing of $3.0 Million Registered Direct Offering Priced at-the-Market Under NASDAQ Rules

ACCESS Newswire February 7, 2023

Ensysce Biosciences, Inc. Announces $3 Million Registered Direct Offering

ACCESS Newswire February 3, 2023

Ensysce Biosciences Announces the Distribution of Series A Preferred Stock to Holders of Its Common Stock

ACCESS Newswire February 1, 2023

Ensysce Biosciences Announces Initiation of Final Stage of Groundbreaking Opioid Overdose Protection Phase 1 Study

ACCESS Newswire January 25, 2023